Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

NCT02548962 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT02548962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02548962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2016
Completion date
June 13, 2018
Enrollment
11 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma